1. Personal details
Name
Date of birth
Place of birth
Nationality
Address
Tel no.
Fax no
E-mail
2. Medical
Experience
: Aristotle Bamias
: 25 April 1962
: Athens
: Greek
: 57A Taygetou st, Vrilissia, 152 35 Athens
: 0030 2103381546, 0030 6944861060
: 0030 2103381511
: abamias@med.uoa.gr
Education
and
Postgraduate
Medical
September 1980-December 1986
Undergraduate Medical Education, Medical School, University of Athens
January 1987- December 1988:
MD Thesis, Medical School, University of Athens
January 1989-January 1993
PhD student
Dept of Clinical Oncology, Hammersmith Hospital, University of London
26 May 1987-16 August 1987
SHO in General Medicine
Evanghelismos Hospital, Athens
17 August 1987-20 June 1988
SHO in General Medicine
3rd Internal Medicine Dept, Agii Anargyri Hospital, Athens
1 February 1993-31 July 1993
SHO in General Medicine
Northern General Hospital, Sheffield
1 August 1993-31 January 1994
SHO in General Medicine/Oncology
Royal Marsden Hospital, Sutton
1 February 1994-31 August 1994
Clinical Research Fellow in GI and Lymphoma Unit
Royal Marsden Hospital, Sutton
1 September 1994-28 February 1995
SHO in General Medicine/Neurology
Oldhurch Hospital, London
1
NHS and University posts held
1 March 1995-31 November 1995
Lecturer /Honorary Registrar in Medical Oncology
St. Bartholomews Hospital, London
27 March 1997- 7 October 2002
Consultant in Medical Oncology
University Hospital, Ioannina, Greece
8 October 2002-27 August 2007
Lecturer in Therapeutics, Medical School, University of Athens
28 August 2007-2 September 2012
Assistant Professor in Therapeutics, Medical School, University of Athens
25 August 2011: Permanent Faculty Member, Medical School, University of
Athens
Present post (since 3 September 2012)
Associate Professor in Therapeutics, Medical School, University of Athens
Affiliation: Oncology/Haematology Unit, ALEXANDRA Hospital, 80 Vasilissis
Sofias Ave., 115 28 Athens, Greece
Tel no. 0030 210 3381546 Fax no. 0030 210 3381511
3. Qualifications, Certificates
25 January 1987
9 May 1990
2 July 1991
15 June 1994
27 November 1995
7 November 1998
Ptychio Iatrikes (MB,BS in Medicine),
University of Athens
Doctorate in Medicine (MD), University of
Athens.
Certificate in Immunology, King’s College,
University of London.
Ph.D., University of London.
Title: The development of a prodrug activation
system for cancer therapy
M.R.C.P. (U.K.)
ΕSMO Certificate
4. Accreditation of specialties
7 March 1996: Internal Medicine, Ministry of Health, Greece
24 May 2000: Medical Oncology, Ministry of Health, Greece
Hellenic Medical Association no. 052965
GMC Registration no: 3422049 (1989-1995; not paid for renewal after my
return to Greece-now in the process of restoration)
2
5. Member of International Scientific Bodies-Societies
1996 Full member of the European School of Medical Oncology (ESMO)
2001 Full member of the American Society of Clinical Oncology (ASCO)
2006 Member of the European Society of Gynaecological Oncology (ESGO)
6. Scholarships, Prizes
1980-1986
1989-1991
1992
1991
2004
2005
2009
Scholarship by the Athenean Club
Scholarship by the Greek Ministry of Economy
Scholarship by the “Alexandros Onassis” Foundation
The Galen Prize by the Hellenic Medical Society, London
First Prize at the 12th Greek National Congress of Medical
Oncology
Second Prize at the 14th Greek National Congress of Medical
Oncology
Prize for the best Poster: «Changes in lymphocytic populations
and autoantibodies resulting from sunitinib treatment of metastatic
renal cell carcinoma (mRCC). Karadimou A, Gavalas N, Sereti E,
Gyftaki R, Lainakis G, Dimopoulos MA, Bamias A. 1st Congrress
Mediteranean Multidisciplinary Oncology Forum, Athens 10-13
September 2009
7. Teaching and Educational activity-duties
6.1. St Bartholomew’s Hospital (1995)
Undergraduate Education
5th year of Medical School, University of London (Physical Examination)
6.2. Ioannina University Hospital (1997-2002)
Undergraduate Education
3rd year of Medical School, University of Ioannina (Physical Examination)
4th year of Medical School, University of Ioannina (Physical Examination)
6th year of Medical School, University of Ioannina (Internal Medicine)
Postgraduate Education
2 Postgraduate Courses
6.3. Medical School, University of Athens (2002-cont)
Undergraduate Education
Faculty member in charge of the subject “ONCOLOGY I”
5th year of Medical School (teaching subject: Therapeutics)
6th year of Medical School (teaching subject: Internal Medicine)
Teaching of Clinical Pharmacology (2006-2010)
Teaching of Gynaecological Oncology (2011-cont)
Teaching of the 3rd Summer School of Oncology, 5th year of all Greek Medical
Schools (2009)
Postgraduate Education
3
Co-ordinator of the Genitourinary Oncology Courses of the Hellenic Society of
Medical Oncology
Teaching at 4 Postgraduate Courses of the Medical School, University of
Athens
Teaching at Postgraduate Courses of Residents in Urology
Participation as a lecturer in numerous Postgraduate courses
Teaching Books (participating author)
Clinical Therapeutics (Medical School, University of Athens)
Clinical Oncology (Medical Schools of all Greek Universities)
Internal Medicine (Medical School, University of Athens)
Urogenital and Gynaecological Oncology (Hellenic Society of Medical
Oncology-3 books)
Supervisor of Medical Theses, Athens University: 8
8. Clinical experience-duties
Major focus: Treatment of genitourinary and gynaecological malignancies
Details of clinical experience and duties
UK (SHO, Clinical Fellow, lecturer in Medical Oncology) (1993-1995)
Internal Medicine (Northern General Hospital, Oldchurch Hospital)
 Management of patients in the Wards
 On call rotation
 Outpatients Clinics
Medical Oncology
(Royal Marsden Hospital, St Bartholomew’s Hospital)
● treatment of GI, GU, lung and ovarian cancer and Lymphomas:
clinical duties in the wards, outpatient clinics and Day Units
● Multidisciplinary meetings for GYN cancers
● on call rotation
University Hospital of Ioannina (Consultant in Medical Oncology) (1997-2002)
● management of patients with solid tumors (focus on GI and GU
malignancies): clinical duties in the wards, outpatient clinics and Day
Unit
● Introduction of the continuous infusion of 5-FU in GI malignancies
● training of residents in medical oncology
● on call rotation (Medical Oncology Dept and A+E).
Present post
Dept Of Clinical Therapeutics, Alexandra Hospital, Athens (Lecturer and
Assistant Professor, Medical school, University of Athens) (2002-cont)
4







Management of Oncology patients (Consultant) in the Wards of the
Dept of Clinical Therapeutics and Outpatients Clinic of the Oncology
Unit on a daily basis
The Unit treats an average of 50 cancer patients/day including solid
tumors and haematological malignancies. The medical personnel
includes 6 Consultants-Faculty members of Athens University and 5
Medical Oncology Registrars. The Dept of Clinical Therapeutics, where
the Unit belongs has 80 General Medicine beds and the medical
personnel covers most of the Medical specialties. Patients of the
Haematology/Oncology Unit who require admission, are admitted to
the Dept of Clinical Therapeutics. The Hospital also has a ITU, ICU and
a CVA Unit. It also hosts the First Obsterics and Gynaecology Dept of
the University of Athens, which includes a very active Gynaecological
Oncology Unit, with 3 Gynaecology Oncology Consultants-members of
the university Faculty. The Gynaecology Oncology Unit is responsible
for the surgical management, while chemotherapy is administered and
managed by the Haematology/Oncology Unit. The Hospital is a referral
center for gynaecological and genitourinary cancer as well as
peripheral stem cell transplantation.
Outpatients Medical Oncology Clinic in Private Suite (twice a week)
Training of Medical Oncology Registrars
On call duty (Consultant) for General Medicine
Rotation as Co-ordinator of the A+E Dept (Medical)
Member of the Gynaecological Oncology multi-disciplinary team
(Alexandra Hospital)
Member of the Genito-Urinary Cancer multi-disciplinary team
(Alexandra-Sismanoglion Hospitals)
9. Research and Laboratory activities
Major fields of research: Genitourinary and Gynaecological Cancer,
Translational Research, Tumor Immunology.
9.1. Detailed description of Research subjects
Doctorate (University of Athens).
● Study of immunohistochemical expression of two monocloncal antibodies in
normal mucosa, polyps and cancer of the colon (publication no. 2).
Ph.D. (University of London) (publication nos 3,4,6,7)
● The experiments were performed at the Imperial Cancer Research Fund
Laboratory and the Pathology Dept, Hammersmith Hospital, London. The
project included:
basic research: production of a monoclonal antibody conjugate, study
in cell culture, production of novel monoclonal and polyclonal
antibodies, experiments to animal models
clinical research: pharmacokinetics of monoclonal antibodies, after
instillation in the bladder of patients with bladder cancer.
5
result: the development of a selective cyanide generating system at
tumor microenvironment
Hammersmith Hospital, London, UK
Regional administration of monoclonal antibodies for caner diagnosis and
treatment (publication nos 1,5).
Royal Marsden Hospital, Sutton, Surrey, UK and University Hospital,
Ioannina, Greece
● use of continuous 5-FU infusion for the treatment of GI malignancies,
pharmacokinetic studies (publication nos 8,9,36).
● translational research (publication nos 21,98).
● clinical research: multicenter Greek studies (publication nos
14,17,19,20,24,25,29,34,35)
Research at current post
● design and conduct of multicenter clinical studies (national and
multinational) (role: study PI, member of Steering Committee or center PI) of
GU and GYN malignancies (publication nos
38,39,48,50,51,56,58,67,70,72,75,78,79,82,84,91,92,94,99,102,119,130,134,
140,143,164).
● development, maintenance, update and analysis of databases of
characteristics, treatment and outcome of patients with GU and GYN cancers
of our Unit. The work on the databases is sponsored by my involvement in
industry-sponsored clinical studies. The statistical team consists, apart from
myself, of Mrs Kakoyiannis (Data Manager), Dr Tzannis (biostatistician) and
Dr C. Bamia (Assistant Professor in Epidemiology, University of Athens) and
involves international collaboration. (publication nos
35,39,48,58,67,75,78,82,92,94,99,102,130,140,143,150,152,154,158).
● side effects of anti-tumor treatment (publication nos
42,45,52,71,112,118,122,123,137,149,153,155,156,161). My studies on
osteonecrosis of the jaw secondary to bisphosphonate therapy have been
used in the development of international guidelines for this manifestation
● Faculty Member in charge of the Research Laboratory of the Dept of
Clinical Therapeutics
The Laboratory has been established since 2004. The main research activity
is focused on the predictive and prognostic role of elements of the immune
response (publication nos 61,85,95,124,128,144,148) in Genitourinary and
Ovarian cancer. The other main interest is angiogenesis (publication nos
22,27,41,47,53,55,64,66,77,81,87,88,103,113,129) and its role in immune
response and resistance to systemic treatment.
The personnel consist of 4 biologists and several postgraduate students. The
costs are covered by my involvement in industry-sponsored clinical studies
as well as by programs sponsored by the Greek state and the EU.
There is tissue bank, which is dedicated to the storage of biological material
of patients with renal, bladder and ovarian cancer, who are managed in our
Unit. The Laboratory is equipped with a flow cytometer, tissue culture, ELISA,
PCR and facilities for Western blot. There is also equipment for
cryopreservation used for stem cell transplantation.
6
9.2. Member of Co-operative Groups
1. Hellenic Co-operative Oncology Group (HECOG)
Co-ordinator of the Quality of Life Working Group (1996-2004)
(publication no 19)
Co-ordinator of the Genitourinary Working Group (2004-2012)
The Working Group has conducted a considerable number of clinical
studies in genitourinary cancer, including two randomized, phase III
trials in urothelial cancer (publication nos
24,28,29,39,58,91,119,120,134). Recently there has been a focus in
translational research studying prognostic and predictive factors in
patients treated with chemotherapy (publication nos 103,113) including
international collaboration.
Member of the Scientific Committee (1996-2012)
2. European Network of Gynaecologic Oncology Trials (ENGOT) Groups
(publication nos 133,158,159)
Representative of Greece-HECOG (2010-2013)
This is the most recent field of international collaboration of the Hellenic
Cooperative Oncology Group aiming to participate in multinational
collaborative studies. HECOG has already participated in two studies,
which I am a member of the Steering Committees.
3. Hellenic Genito-Urinary Cancer Group (HGUCG)
Founding Member and Chair of the the Directing Committee of
HGUCG, which includes Greek Medical Oncologists, Urologists and
Scientists with an interest in research on GU Cancer. The aim of this
group is to provide a platform for the collaboration of these specialists,
apply high standards of care and promote research in GU Cancer.
9.3. Sponsored research
1. Hellenic Society of Medical Oncology
2003-2004 5,500€
Study of the expression of COX-2 in urothelial carcinoma
2004-2005 5,870 €
Study of lymphocytic populations and cytokines in ascites from ovarian
cancer
2012-2013 6,000 €
Study of angiogenic factors in the ascetic fluid from patients with advanced
ovarian cancer
2. University of Athens (2006-2009): 10000€
Study of the prognostic significance of molecular and angiogenic factors in
ovarian canrcinoma
3. EEC and Ministry of Education of Greece (2004-2007): 50,000€
In vitro and in vivo study of the immune anti-tumor response in patients
with ovarian cancer. Prognostic and predictive value
7
4. Ministry of Development of Greece: 66,000€ (Greek-USA collaboration,
Co-Investigator)
Combinational immunotherapy for the best anticancer action of NK cells. A
study in vitro and in experimental models.
5. Ministry of Health of Greece (2005-2006): 14,650€ (Co-Investigator)
In vitro augmentation of cytotoxic ability of human ΝΚ cells with cytokines
and their utility in in vivo models of cell immunotherapy of cancer.
6.
FP7-REGPOT-2011 programe (Code: REGPOT-CT-2011-284460
INsPiRE) 2011-2014: 3.722.000€ (Co-Investigator)
Integrating the emerging research potential of the University of Athens
cancer Research group in the European research area
7.
Research funding by several pharmaceutical companies for the research
activities of the Laboratory of the Dept of Clinical Therapeutics.
9.4. Research collaboration
9.4.1. Greek Centers
1. Α’ Dept of Obstetrics and Gynaecology, University of Athens (see list of
publications)
2. Β’ Urology Dept, University of Athens (see list of publications)
3. Pathology Dept, University of Athens (publication nos 87,103,113)
4. Laboratory of Epidemiology, University of Athens (publication nos
52,71,112,150,152,154,158)
5. Immunology Laboratory, University of Athens (publication nos
61,85,95,116,148)
6. Institute of Biological Research and Biotechnology, Athens, Greece
(publication no 163)
9.4.2. International collaboration
1. Department of Medical Oncology, Yale University, School of Medicine
(Assistant Professor A. Psyrri) (publication nos 53,55,66,77)
2. French collaborative national database (Professor M. Roupret, publication
no 150)
3. Harvard Medical School (Professor J. Rosenberg, Professor J. Bellmunt)
4. Georges Pompidou Hospital, Paris, France (Professor S. Oudard,
publication no 182)
5. University of Pavia, Italy (Professor C. Porta)
6. Mount Sinai, School of Medicine (Dr M. Galsky, Dr S. Grossman)
(publication no 176,179-181)
7. Invited Professor by the Oncology Dept, Hopital Universitaire de Geneve
(Prof. P-Y. Dietrich) for Urogenital Cancer (March-August 2012)
9.5. Participation in international multicenter trials
9.5.1. Member of Steering Committee
AURELIA (platinum-resistant ovarian cancer, oral presentation at
ASCO 2012)
TRINOVA-3 (1st line ovarian cancer, accruing)
8
PRINCIPAL (pazopanib in metastatic renal cell carcinoma, still
accruing)
9.5.2. Institution PI: 7 (publication no. 164)
9.5.3. Investigator: 10 (publication no. 168)
10. International Faculty Member, Consensus Groups
1. Member of the Faculty of Urogenital Cancer of the Educational
Committee of the European School of Medical Oncology (ESMO) (20122014).
2. Guidelines for the management of prostate cancer by international
Group of Experts (publication 110)
3. Member of the ESMO Guidelines Working Group for testicular cancer
(publication nos 138,139).
4. Member of numerous international Advisory Boards
11. Editorial Board of international journals
1.
2.
3.
4.
5.
Forum of Clinical Oncology (2010-cont’d)
Open Access Urology (2009-cont’d)
Annals of Urology (up to 2010)
CML Kidney Cancer (up to 2010)
Experimental Hematology & Oncology (2012-cont’d)
12. Reviewer
1.
2.
3.
4.
5.
6.
7.
8.
9.
Oncology-Basel
Annals of Oncology
European Urology
Cancer Chemotherapy Pharmacology
Clinical Cancer Research
World Journal of Urology
Expert Review of Anticancer Therapy
Nature Reviews
International Journal of Urology
etc
13. Editor
1. RCC CASE STUDIES: Guest Editor of the first edition
2. Achieving Optimal Outcomes in Patients with Cardiovascular
Complications. Therapy Management Series. Eds: M. Schmidinger, J. BurgerKlein, A. Bamias.
14. Invited speaker
to 33 international congresses (selected
presentations below):
Special Symposium: Management of renal cancer. Introduction.
31rst ESMO Congress 2006
9
Poster Discussion: “Genitourinary cancer”. Discussant 31st ESMO Congress,
2006.
Therapeutic options for stage-I seminoma. Surveillance.
3rd World Congress on Controversies in Urology, 2010
Renal tumors: case discussion debates.
3rd World Congress on Controversies in Urology 2010
Neoadjuvant or adjuvant chemotherapy when the renal function is impaired:
for some patients, for all patients, for no patients?
3rd World Congress on Controversies in Urology. 2010
Round Table. Combination therapy with targeted agents is the future.
EAU Congress, Barcelona 2010
Treating through co-morbidities
2nd Annual Conference of Renal Cancer Experts (CORE). Hamburg April
2011.
Interactive Satellite Symposium: “Navigating therapeutic opportunities and
investigational approaches for patients with Genitourinary Malignancies”.
ESMO Congress,Stockholm 2011
Oral abstract presentations in selected congresses:
ASCO: 2 (GU session)
ESMO: 2 (GI and GU session)
Chair in Round Tables/Sessions in international Congresses/Meetings: 7
15. Social Activities
Participation in awareness broadcasts, articles and interviews on issues of
cancer diagnosis and management in tv and paper and electronic press
16. Publications (excluding Greek publications)
16.1. Analysis of publications
Abstracts in international Congresses: 92
Chapters in English books: 11
Publications in peer reviewed journals: 184
Publication subject
Application of monoclonal antibodies in oncology: 7
GI cancer: 19
GU cancer: 59
GYN cancer: 55
Other malignancies: 28
10
Complications of anti-cancer therapy: 15
Cardiology: 1
1st author: 55 (32%)
2nd author: 19 (10%)
Last author: 36 (20%)
Origin of work
Greece: 157
International: 27
Content
Guidelines: 5
Basic research: 6
Clinical studies: 97
Translational research: 31
Reviews: 21
Case reports: 13
Editorials: 5
Letters to the Editor: 4
Publications accompanied by an Editorial: 3
Publication impact factor (June 2012): 632,293 (mean: 3,78)
Citations (February 2013) (scopus): 4072
H-index (February 2013): 33
16.2. Publications in peer-reviewed journals (citations updated at June
2012)
1. Kalofonos HP, Cosmas C, Pawlikowska TRB, Bamias A, Snook D, Dhokia
B, Sivolapenko GB, Courtenay-Luck NS, Epenetos AA. Immunolocalisation
of testicular tumors using radiolabelled monoclonal antibody to placental
alkaline phosphatase. J Nucl Med Allied Sci, 34: 294-298, 1990.
(citations: 4)
2. Anagnostaki E, Skarlos D, Tamvakis N, Psaropoulou P, Blana E, Bamias
A, Legaki S, Aravantinos G, Deliveliotis C, Dimopoulos K.
Immunohistochemical and immunocytochemical study of bladder
carcinomas using the epithelium-specific, tumour -associated monoclonal
antibodies HMFG1 and AUA1. Br J Cancer, 62(suppl x): 52-56, 1990.
(citations: 11)
11
3. Bamias A, Keane P, Krausz T, Williams G, Epenetos AA. Intravesical
administration of radiolabelled antitumor monoclonal antibody in bladder
carcinoma. Cancer Res, 51: 724-728, 1991. (citations: 32)
4. Rowlinson-Busza G, Bamias A, Krausz T, Epenetos AA. Uptake and
distribution of specific and control monoclonal antibodies in subcutaneous
xenografts following intratumour injection. Cancer Res, 51: 3251-3256,
1991. (citations: 21)
5. Hird V, Vorhoeyen M, Badley RA, Price D, Snook D, Kosmas C, Gooden C,
Bamias A, Meares C, Lavender JP, Epenetos AA. Tumour localisation with
a radioactively labelled reshaped human monoclonal antibody. Br J
Cancer, 64: 911-914, 1991. (citations: 36)
6. Bamias A, Epenetos AA. Two step strategies for the diagnosis and
treatment of cancer with bioconjugates. Antibody, Immunoconjugates
and Radiopharmaceuticals, 5(4): 385-395, 1992. (citations: 17).
7. Bamias A, Bowles MJ, Krausz T, Williams G, Epenetos AA. Intravesical
administration of indium-111-labelled HMFG2 monoclonal antibody in
superficial bladder carcinomas. Int J Cancer 54: 899-903, 1993 (citations:
13)
8. Bamias A, Cunningham D, Nicolson V. Adjuvant chemotherapy for
oesophagogastric cancer with Epirubicin, Cisplatin & infusional 5Fluorouracil (ECF): A Royal Marsden pilot study. Br J Cancer, 71(3): 583587, 1995. (citations: 14)
9. Bamias A, Hill M, Cunningham D, Norman A, Ahmed F, Webb A, Watson
M, Hill A, Nicolson M, O’Brien M.E, Evans C, Nicolson V. Epirubicin,
Cisplatin and protracted venous infusional 5-Fluorouracil (ECF) for
gastroesophageal adenocarcinoma: Response, toxicity, quality of life, and
survival. Cancer, 77(10): 1978-1985, 1996. (citations: 71)
10.Gossios K, Tsianos E, Nicolson V, Bamias A, Cunningham D, Husband J.
CT evaluation of the resectability of gastric cancer post chemotherapy.
Abdominal Imaging, 21:293-298, 1996. (citations: 5)
11.Ngi VWK, Husband GES, Nicolson VMC, Minty I, Bamias A. CT evaluation
of treatment response in advanced gastric cancer. Clinical Rad, 51: 214220, 1996. (citations: 8)
12.Bamias A, Pavlidis N. The management of pleural mesothelioma. SouthAmerican Journal of Cancer 2(1): 97-101, 1997.
13.Bamias A, Pavlidis N. Systemic chemotherapy in gastric cancer: Where do
we stand today? Oncologist, 3: 171-177, 1998. (citations: 9).
14.Dimopoulos M, Bakoyiannis C, Georgoulias V, Moulopoulos L, Deliveliotis C,
Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D,
12
Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A,
Kosmidis P. Docetaxel and Cisplatin combination chemotherapy in advanced
carcinoma of the urothelium: a multicenter phase II study of the Hellenic
Cooperative Oncology Group. Ann Oncol, 10 (11): 1385-1388, 1999.
(citations: 48)
15.Katsimbri P, Bamias A, Peponis I, Froudarakis M, Konstantopoulos S,
Pavlidis N. Endobronchial metastases secondary to solid tumours: Report of
eight cases and review of the literature. Lung Ca, 28(2): 163-170, 2000.
(citations:49)
16.Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy- induced
alopecia using an effective scalp cooling system. Eur J Cancer, 36: 766771, 2000. (citations: 37)
17.Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A,
Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV. Phase II study of
Temozolamide in heavily pretreated patients with brain metastases from
solid tumors. Ann Oncol, 12(2): 249-254, 2001. (citations: 106)
18.Bamias A, Baltayiannis G, Kamina S, Fatouros M, Lymperopoulos E,
Agnanti N, Tsianos E, Pavlidis N. Rectal metastases from lobular
carcinoma of the breast: report of a case and literature review. Ann Oncol,
12(5): 715-718, 2001. (citations: 23)
19.A. Bamias, G. Aravantinos, C. Kalofonos, N. Timotheadou, V. Siafaka, I.
Vlahou, D. Janinis, D. Pectasides, N. Pavlidis, G. Fountzilas. Prevention of
anemia in patients with solid tumors receiving Platinum-based
chemotherapy by recombinant human erythopoietin (rHuEPO): a
prospective, open label, randomized trial by the Hellenic Cooperative
Oncology Group. Oncology 64(2): 102-110, 2003. (citations: 31)
20.HP Kalofonos, D. Kardamakis, A. Bamias, D.V. Skarlos, P. Papakostas, D.
Bafaloukos, A. Sakantamis, N. Pavlidis, G. Fountzilas. Adjuvant
chemotherapy using CPT-11, Leucovorin plus bolus 5-Fluorouracil and
Radiotherapy in patients with rectal cancer. A feasibility study. Anticancer
Res 23: 1687-1692, 2003. (citations: 7)
21. Bamias
AT, Bai MC, Agnantis NJ, Michael MC, Alamanos YP, Stefanaki
SV, Razi ED, Skarlos DV, Kappas AM, Pavlidis NA. Prognostic significance
of the deleted in colorectal cancer (DCC) gene expression in high risk
resected gastric carcinoma. Cancer Invest 21(3): 333-340, 2003.
(citations: 4)
22. A.
Bamias, M. Chorti, C. Deliveliotis, N. Trakas, A. Skolarikos, B.
Protogerou, S. Legaki, G. Tsakalou, N. Tamvakis, M.A. Dimopoulos. The
prognostic significance of CA 125, CD44 and Epithelial Membrane Antigen
(EMA) in renal cell carcinoma. Urology 62(2); 368-373, 2003. (citations:
11)
13
23.A. Bamias, D. Papamichael, K. Syrigos, N. Pavlidis. Phase II study of
irinotecan and mitomycin C in 5-Fluorouracil pretreated patients with
advanced colorectal and gastric cancer. J Chemother 15(3): 275-81, 2003.
(citations: 11)
24.A. Bamias, G. Aravantinos, Ch. Deliveliotis, D. Bafaloukos, Ch. Kalofonos,
N. Xiros, A. Zervas, D. Mitropoulos, E. Samantas, D. Pectasides, P.
Papakostas, D. Gika, C. Kourousis, A. Koutras, C. Papadimitriou, C.
Bamias, P. Kosmidis, M.A. Dimopoulos. Docetaxel and Cisplatin with
Granulocyte-colony stimulating factor (G-CSF) versus M-VAC with G-CSF
in advanced urothelial carcinoma: a multicenter, randomised, phase III
study conducted by the Hellenic Cooperative Oncology Group. J Clin
Oncol 22(2): 220-228, 2004. (citations: 91)
25.H.P. Kalofonos, D. Skarlos, D. Bafaloukos, P. Papakostas, A. Bamias, J.
Janinis, E. Timotheadou, G. Kouvatseas, M. Stavropoulos, T.
Economopoulos, G. Fountzilas. A phase II study with CPT-11 plus
Leucovorin and bolus iv 5-Fluorouracil in patients with advanced colorectal
carcinoma. Cancer Investigation 21(6): 855-862, 2003. (citations: 8)
26.A. Bamias, M.A. Dimopoulos. Angiogenesis in human cancer: implications
in cancer therapy. Eur J Int Med 14: 459-469, 2003. (citations: 26)
27.Athanasios Protopapas, Emmanuel Diakomanolis, Aristotle Bamias,
Spyros Milingos, Sonia Markaki, Christos Papadimitriou, AthanasiosMeletios Dimopoulos, Stylianos Michalas. The prognostic significance of
the immunohistochemical expression of p53, bcl-2, c-erb-2 and cathepsinD in ovarian cancer receiving platinum with cyclophosphamide or paclitaxel
chemotherapy. Eur J Gynaec Oncol 25: 225-229, 2004. (citations: 18)
28.Bamias A, Deliveliotis Ch, Aravantinos G, Kalofonos Ch, Karayannis A,
Dimopoulos MA. Adjuvant chemotherapy with Paclitaxel and Carboplatin in
patients with advanced bladder cancer: a study by the Hellenic Cooperative
Oncology Group. J Urol, 171(4): 1467-1470, 2004. (citations: 13)
29.A. Bamias, Ch. Deliveliotis, G. Fountzilas, D. Gika, A. Anagnostopoulos,
M.P. Zorzou, E. Kastritis, C. Konstantinidis, P. Kosmidis, M.A. Dimopoulos.
Adjuvant chemotherapy with Paclitaxel and Carboplatin in patients with
advanced carcinoma of the upper urinary tract: a study by the Hellenic
Cooperative Oncology Group. J Clin Oncol 22: 2150-2154, 2004.
(citations: 31)
30.Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of
Psoriasis after Treatment with an EGFR Tyrosine Kinase Inhibitor. Acta
Derm Venereol 2004; 84: 308-309 (Letter). (citations: 13)
31.V. Eleutherakis – Papaiakovou, A. Bamias, MA. Dimopoulos. Thalidomide
in cancer medicine. Ann Oncol 15:1151-1160, 2004. (citations: 45)
14
32.Protogerou V, Moschou M, Antoniou N, Varkarakis J, Bamias A,
Deliveliotis C. Modified S-pouch neobladder vs ileal conduit and a matched
control population: a quality-of-life survey. BJU Int 94: 350-354, 2004.
(citations: 19)
33.A. Bamias, C. Deliveliotis, A. Karayiannis, I. Varkarakis, I. Zervas, D.
Pantazopoulos, D. Gika, M.A. Dimopoulos. Neoadjuvant chemotherapy
with Docetaxel and Cisplatin in patients with high-risk respectable bladder
carcinoma: long term results. Eur Urol 46: 344-351, 2004. (citations: 7)
34.Helena Linardou, Gerassimos Aravantinos, Eleni Efstathiou, Charalambos
Kalofonos, Athanasios Anagnostopoulos, Charalambos Deliveliotis,
Dimitrios Bafaloukos, Meletios Athanasios Dimopoulos, Aristotelis Bamias.
Gemcitabine and Carboplatin combination as first-line treatment in elderly
and unfit for cisplatin-based chemotherapy patients with advanced bladder
carcinoma. A phase II study of the Hellenic Co-operative Oncology Group.
Urology, 64(3):479-484, 2004. (citations: 44)
35.MA Dimopoulos, C Papadimitriou, G Hamilos, E Efstathiou, G Vlahos, A
Rodolakis, G Aravantinos, HP Kalofonos, C Kouroussis, D Gika, D Skarlos,
A Bamias. Treatment of Ovarian Germ Cell Tumors with a three-day
bleomycin, etoposide and cisplatin regimen: A prospective multicenter
study. Gynecol Oncol 93: 695-700, 2004. (citations: 14)
36.Bamias A, Syrigos K, Fountzilas G, Tzamakou E, Soulti K, Karavasilis V,
Alamanos Y, Christodoulou C, Pavlidis N. Intensified Bimonthly Cisplatin
With Bolus 5-Fluorouracil, Continuous 5-Fluorouracil and High-Dose
Leucovorin (LV5FU2) in Patients With Advanced Gastrointestinal
Carcinomas: A Phase I Dose-Finding and Pharmacokinetic Study. Am J
Clin Oncol 27: 465-471, 2004. (citations: 2)
37.Aristotle Bamias, Meletios A. Dimopoulos. Thalidomide and
Immunomodulary drugs in the treatment of cancer. Expert Opin Invest
Drugs 14: 45-55, 2005. (citations: 19)
38.E. Efstathiou, G. Bozas, A. Kostakopoulos, E. Kastritis, Ch. Deliveliotis, N.
Antoniou, D. Skarlos, C. Papadimitriou, M.A. Dimopoulos, A. Bamias.
Combination of Docetaxel, Estramustine Phosphate and Zoledronic acid in
androgen independent metastatic prostate cancer: efficacy, safety and
clinical benefit assessment. Urology 65:126-130, 2005. (citations: 23)
39.Aristotle Bamias, Eleni Efstathiou, Lia A. Moulopoulos, Dimitra Gika,
George Hamilos, Markela P. Zorzou, Constantina Kakoyiannis, Efstathios
Kastritis, George Bozas, Christos Papadimitriou, Meletios A. Dimopoulos.
The outcome of elderly patients with advanced urothelial carcinoma after
platinum-based combination chemotherapy. Ann Oncol 16:307-313, 2005.
(citations: 19)
40.C. Christodoulou, D. Bafaloukos, E. Linardou, G. Aravantinos, A. Bamias,
C. Karina, G. Klouvas, D. Skarlos. Temozolomide (TMZ) combined with
15
cisplatin (CDDP) in patients with brain metastases from solid tumors:
Phase II study. J Neurooncol 71:61-65, 2005. (citations: 41)
41.Deliveliotis Ch, Georgoulakis J, Skolarikos A, Trakas N, Varkarakis J,
Albanis S, Protogerou B, Bamias A. DNA ploidy as a prognostic factor in
muscle invasive transitional cell carcinoma of the bladder. Urol Res 33: 3943, 2005. (citations: 8)
42.Markela P. Zorzou, Eleni Efstathiou, Eleni Galani, Georgios Bozas,
Efstathios Kastritis, Christos Papadimitriou, Meletios A. Dimopoulos,
Aristotle Bamias. Carboplatin hypersensitivity reactions: a single insitution
experience. J Chemother 17:104-10, 2005. (citations: 6)
43. N. Xiros, P. Papakostas, T. Ecomopoulos, G. Samelis, E. Efstathiou, E.
Kastritis, HP. Kalofonos, A. Onyenadum, D. Skarlos, A. Bamias, H. Gogas,
D. Bafaloukos, E. Samantas, P. Kosmidis. Carboplatin plus Gemcitabine in
patients with inoperable or metatstatic pancreatic cancer. A phase II
multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol
16: 773-779, 2005. (citations: 12)
44.Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos
T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina
M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G,
Kalfarentzos F, Fountzilas G. Irinotecan or oxaliplatin combined with
leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal
cancer: a multicenter, randomized, phase II study. Ann Oncol 16(6): 869877, 2005. (citations: 32)
45.George Chamilos, Aristotle Bamias, Eleni Efstathiou, Pagona M. Zorzou,
Efstathios Kastritis, Evagelos Kostis, Christos Papadimitriou, Meletios A.
Dimopoulos. Outpatient treatment of low-risk neutropenic fever in cancer
patients, with oral moxifloxacin. Cancer 103(12):2629-2635, 2005.
(citations: 34)
46.Evangelos
Briasoulis,
Epameinondas
Samantas,
Haralambos
Kalofonos,
Dimosthenis Skarlos,
Thomas Makatsoris,
Christos
Cristodoulou,
George
Fountzilas,
Aristotle
Bamias,
Athanasios-Meletios Dimopoulos, Paris Kosmidis, Nicholas Pavlidis.
Phase I study of etoposide, cisplatin and irinotecan triplet
in patients with advanced stage small cell lung cancer. Cancer Chem
Pharmacol 56(5):521-528, 2005. (citations: 4)
47.Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis
C, Dimopoulos MA. Bcl-2 protein and DNA ploidy in renal cell carcinoma:
Do they affect patient prognosis? Int J Urol 12(6):563-569, 2005. (citations:
2)
48.Aristotle Bamias, Georgios Hamilos, Eleni Efstathiou, Maria
Vassilakopoulou, Christos Papadimitriou, Alexandros Rodolakis, Dimitrios
Mitsibounas, Georgios Vlahos, Meletios A. Dimopoulos. Late relapse of
16
epithelial ovarian cancer: a single institution experience. Eur J Gynecol
Oncol 26: 439-442, 2005.
49.G. Fountzilas, C. Tolis, A. Kalogera-Fountzila, D. Misailidou, P. Tsekeris,
M. Karina, A. Nikolaou, E. Samantas, T. Makatsoris, E. Athanassiou, D.
Skarlos, A. Bamias, N Zamboglou, T Economopoulos, S Karanastassi, N
Pavlidis, J Daniilidis. Paclitaxel, cisplatin, leucovorin and coninuous infusion
fluorouracil followed by concomitant chemoradiotherapy for locally
advanced squamous cell carcinoma of the head and neck. A Hellenic
Cooperative Oncology Group Phase II study. Med Oncol 22: 269-279,
2005. (citations: 7)
50.Aristotle Bamias, George Basdanis, Ioannis Xanthakis, Nicholas Pavlidis,
George Fountzilas. Prognostic factors in patients with colorectal cancer
receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis
of two randomized studies. Int J Gastrointest Cancer 36:29-38, 2005.
(citations: 1)
51.E. Kastritis, A. Bamias, E. Efstathiou, D. Gika, G. Bozas, MP. Zorzou, K.
Sarris, C. Papadimitriou, MA Dimopoulos. The outcome of advanced or
recurrent non-squamous carcinoma of the uterine cervix after platinumbased combination chemotherapy. Gynecol Oncol 99: 376-382, 2005.
(citations: 12)
52. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas
G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E,
Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with
bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587,
2005. (citations: 489)
53.Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S,
Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA.
Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase
Inhibitor p27 independently Predict for Survival in Epithelial Ovarian
Cancer. Clin Cancer Res. 11: 8384-8390, 2005. (citations: 18)
54.Bamias A, Dimopoulos MA. Neoadjuvant chemotherapy in invasive
bladder cancer. Expert Rev Anticancer Ther. 5: 993-1000, 2005.
55.Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S,
Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of epidermal
growth factor receptor expression level on survival in patients with epithelial
ovarian cancer. Clin Cancer Res. 11(24):8637-8643, 2005. (citations: 56)
56.Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou
CA, Markaki S, Dimopoulos MA. Adjuvant chemotherapy with paclitaxel
and carboplatin in non-endometrioid carcinoma of the uterus. Eur J
Gynaecol Oncol; 26: 627-631, 2005. (citations: 5)
17
57.Bozas G, Anagnostou D, Tassidou A, Moulopoulos LA, Bamias A,
Dimopoulos MA. Extranodal non-Hodgkin’s lymphoma presenting as an
abdominal wall mass. A case report and review of the literature. Leukemia
& Lymphoma 47: 329-332, 2006. (citations: 4)
58.A. Bamias, L.A. Moulopoulos, A. Koutras, G. Aravantinos, G. Fountzilas,
D. Pectasides, E. Kastritis, D. Gika, D. Skarlos, H. Linardou,
H.P.Kalofonos, M.A. Dimopoulos. Gemcitabine and Carboplatin
combination as first-line treatment in patients with advanced urothelial
carcinoma. A phase II study of the Hellenic Co-operative Oncology Group.
Cancer 106: 297-303, 2006. (citations: 28)
59.Bamias A, Dimopoulos MA. Inhibition of angiogenesis: common theme for
cancer and atheromatosis? Hellenic J Cardiol 47(1):11-12, 2006.
60.Papakostas P, Tsavdaridis D, Kosmidis P, Kalofonos HP, Sakantamis A,
Janinis D, Skarlos D, Bafaloukos D, Bamias A, Xiros N, Fountzilas G.
Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as
first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative
Oncology Group phase II study. Gastric Cancer 9: 26-31, 2006. (citations:
5)
61.M. Skopeliti, IF Voutsas, P. Klimenzou, M. Tsiatas, A. Beck, A. Bamias, M.
Moraki, E. Livaniou, M. Neagu, W. Voelter, OE Tsitsilonis. The
immunologically active site of prothymosin a is located at the carboxyterminus of the polypeptide. Evaluation of its in vitro effects in cancer
patients. Cancer Immunol Immunother 55: 1247-1257, 2006. (citations:
11)
62.Ioanna Dimopoulou, Aristotelis Bamias, Panagiotis Lyberopoulos, Meletios
A. Dimopoulos. Pulmonary toxicity from novel antineoplastic agents. Ann
Oncol 17: 372-379, 2006. (citations: 31)
63.Aristotle Bamias, Ioannis Tiliakos, Maria-Dionysia Karali, Meletios A.
Dimopoulos. Systemic chemotherapy in inoperable or metastatic bladder
cancer. Ann Oncol 17: 553-561, 2006. (citations: 19)
64.Evangelos Terpos, Athanasios Anagnostopoulos, Efstathios Kastritis,
Aristotelis
Bamias,
Konstantinos
Tsionos,
Meletios-Athanassios
Dimopoulos. Abnormal bone remodelling and increased levels of
macrophage inflammatory protein-1 alpha (MIP-1a) in Waldenstrom
macroglobulinaemia. Br J Haematol 133: 301-304, 2006. (citations: 7)
65.Bozas G, Tassidou A, Moulopoulos LA, Constandinidis C, Bamias A,
Dimopoulos MA. Non-Hodgkin’s Lymphoma of the renal pelvis. Clin
Lymphoma & Myeloma 6:404-406, 2006. (citations: 2)
66.Psyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp
RL, Rimm DL, Dimopoulos MA. Evaluation of the prognostic value of
cellular inhibitor of apoptosis protein in epithelial ovarian cancer using
18
automated quantitative protein analysis. Cancer Epidemiol Biomarkers
Prev 2006;15:1179-1183. (citations: 2)
67.E.Kastritis, E. Efstathiou, D. Gika, G. Bozas, V. Koutsoukou, C.
Papadimitriou, G. Pissakas, M.A. Dimopoulos, A. Bamias. Brain
metastases as isolated site of relapse in patients with epithelial ovarian
cancer previously treated with platinum and paclitaxel-based
chemotherapy. Int J Gynecol Cancer 2006; 16: 994-999. (citations: 7)
68.E. Kastritis, L.A. Moulopoulos, E. Politi, E. Kostis, G. Pissakas, M.A.
Dimopoulos, A. Bamias. Intramedullary spinal cord and leptomeningeal
metastases in a patient with carcinoma of the uterine cervix. Gynecol
Oncol 2006; 102: 124-127. (citations: 7)
69.Aristotle Bamias, Alexandros Rodolakis, Meletios A. Dimopoulos. Current
treatment of relapsed ovarian cancer. CCTR 2006; 2: 211-221.
70.George Bozas, Meletios A. Dimopoulos, Efstathios Kastritis, Eleni
Efstathiou, Vassiliki Koutsoukou, Alexandros Rodolakis, George Vlahos,
Zannis Voulgaris, Theoharis Papageorgiou, Dimitra Gika, Christos
Papadimitriou, Aristotle Bamias. Young age is associated with favorable
characteristics but is not an independent prognostic factor in patients with
epithelial ovarian cancer (EOC): a single intitution experience. Oncology
2006; 70: 265-272. (citations: 6)
71.Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D,
Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis
of the jaw in patients with multiple myeloma treated with bisphosphonates:
evidence of increased risk after treatment with zoledronic acid.
Haematologica 2006;91:968-971. (citations: 150)
72.Aristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, Alexandros
Rodolakis, Georgios Vlahos, Zannis Voulgaris, Georgios Bozas, Georgios
Fountzilas, Gerassimos Aravantinos, Evagelia Razis, Dimitra Gika,
Meletios A. Dimopoulos. Four cycles of Paclitaxel and Carboplatin as
adjuvant treatment in early-stage ovarian cancer: a six-year experience of
the Hellenic Cooperative Oncology Group. BMC Cancer 2006; 6: 228.
(citations: 3)
73.George Fountzilas, Pavlos Papakostas, Urania Dafni, Thomas Makatsoris,
Maria Karina, Anna Kalogera-Fountzila, Nicholaos Maniadakis, Gerasimos
Aravantinos, Konstantinos Syrigos, Aristotelis Bamias, Christos
Christodoulou, Theofanis Economopoulos, Haralabos P. Kalofonos,
Angelos Nikolaou, Nikos Angouridakis, George Stathopoulos, Dimitrios
Bafaloukos, Nicholas Pavlidis, John Daniilidis. Paclitaxel and Gemcitabine
vs Paclitaxel and Pegylated Liposomal Doxorubicin in advanced non–
nasopharyngeal head and neck cancer. An efficacy and cost analysis
randomized study conducted by the Hellenic Cooperative Oncology Group.
Ann Oncol 2006; 1560-1567. (citations: 7)
19
74.L. Kostadima, G. Pentheroudakis, M.A. Dimopoulos, D. Pectasides, H.
Gogas, U. Stropp, Ch.Christodoulou, E. Samantas, R. Wirtz, G. Hennig, D.
Bafaloukos, P. Arapantoni, H.P. Kalofonos, P.Papakostas, T.
Economopoulos, A. Bamias, G. Fountzilas, N. Pavlidis. Survivin and
Glycodelin transcriptional activity in node-positive early breast cancer:
mRNA expression of two key regulators of cell survival. Breast Cancer
Res Treat 2006; 100: 161-167. (citations: 2)
75. Kastritis E, Dimopoulos MA, Antoniou N, Deliveliotis C, Chrisofos M,
Skolarikos A, Gika D, Bamias A. The outcome of patients with advanced
pure squamous or mixed squamous and transitional urothelial carcinomas
following platinum-based chemotherapy. Anticaner Res 2006; 26:38653869. (citations: 8)
76.G Mountzios, G Pavlakis, E Terpos, G Sakorafas, K Revelos, A
Bamias, N Nikolaou, P Papasavas, J-C Soria and MA Dimopoulos.
Concurrent development of testicular seminoma and choriocarcinoma
of the superior mediastinum, presented as cervical mass: a case
report and implications about pathogenesis of germ-cell tumours. BMC
Pathology 2006; 6: 8. (citations: 2)
77.Aristotle Bamias, Ziwei Yu, Paul M. Weinberger, Sofia Markakis, Diane
Kowalski, Robert L. Camp, David L. Rimm, Meletios A. Dimopoulos and
Amanda Psyrri. Automated Quantitative Analysis of DCC Tumor
Suppressor Protein in Ovarian Cancer Tissue Microarray Shows
Association with β-catenin Levels and Outcome in Patients with Epithelial
Ovarian Cancer. Ann Oncol 2006; 17: 1797-1802. (citations: 4)
78.Efstathios Kastritis, Georgios Bozas, Vassiliki Koutsoukou, Zannis
Voulgaris, Georgios Vlahos, Alexandros Rodolakis, Dimitra Gika; Christos
Papadimitriou, Meletios-Athanasios Dimopoulos, Aristotle Bamias. The
impact of age in the outcome of patients with advanced or recurrent
cervical cancer after platinum based chemotherapy. Gynecol Oncol 2007;
104: 372-376. (citations: 5)
79.George Bozas, Aristotle Bamias, Vassiliki Koutsoukou, Eleni Efstathiou,
Dimitra Gika, Christos A. Papadimitriou, Meletios A. Dimopoulos. Biweekly
Gemcitabine and Cisplatin in Platinum Resistant/Refractory, PaclitaxelPretreated, Ovarian and Peritoneal Carcinoma. Gynecol Oncol 2007; 104:
580–585. (citations: 11)
80.Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A,
Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Group MA.
Renal failure in multiple myeloma: Incidence, correlations, and prognostic
significance. Leuk Lymphoma 2007 48(2):337-41. (citations: 43)
81.Giannis Mountzios, Meletios-Athanassios Dimopoulos, Aristotelis Bamias,
George Papadopoulos, Efstathios Kastritis, Konstantinos Syrigos, George
Pavlakis, EvangelosTerpos. Abnormal bone remodeling process is due to
an imbalance in the Receptor Activator of Nuclear Factor–kB Ligand
20
(RANKL)/Osteoprotegerin (OPG) axis in patients with solid tumors
metastatic to the skeleton. Acta Oncologica 2007;46(2):221-9. (citations:
25)
82.Eleni Efstathiou, Meletios A. Dimopoulos, George Bozas, Efstathios
Kastritis, Lia A. Moulopoulos, Alexandros Rodolakis, George Vlahos,
Dimitra Gika, Christos Papadimitriou, Aristotelis Bamias. Advanced
Epithelial Ovarian Cancer in the Elderly: Chemotherapy Tolerance and
Outcome. Anticancer Res 2007; 27(1B):611-7. (citations: 4)
83.CA Papadimitriou, Zorzou MP, Markaki S, A Rodolakis, Z Voulgaris, G
Bozas, E Kastritis, A Bamias, D Gika, MA Dimopoulos. Anthracyclinebased adjuvant chemotherapy in early-stage uterine sarcomas: long-term
results of a single institution experience. Eur J Gynaec Oncol 2007; 18:
109-116. (citations: 5)
84.Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C,
Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA.
Reversibility of renal failure in newly diagnosed multiple myeloma patients
treated with high dose dexamethasone-containing regimens and the impact
of novel agents. Haematologica 2007;92(4):546-9. (citations: 57)
85.Aristotle Bamias, Marinos Tsiatas, Eutychia Kafantari, Christina Liakos,
Alexandros Rodolakis, Zannis Voulgaris, George Vlahos, Theocharis
Papageorgiou,
Ourania
Tsitsilonis,
Christina
Bamia,
George
Papatheodoridis, Ekaterini Politi, Athanasios Archimandritis, Aristidis
Antsaklis, Meletios A Dimopoulos. Significant differences of lymphocytes
isolated from ascites of patients with ovarian cancer compared to blood and
tumor lymphocytes. Association of CD3+CD56+ cells with platinum
resistance. Gynecol Oncol 2007; 106: 75-81. (citations: 15)
86.Aristotle Bamias. Case Report 1. Sunitinib malate in patients with preexisting haematological abnormalities. Eur J Cancer 2007; 7(Suppl 5): 2829.
87.H Gakiopoulou, P Korkolopoulou, G Levidou, I Thymara, A Saetta, C
Piperi, N Givalos, I Vassilopoulos, K Ventouri, A Tsenga, A Bamias, M-A
Dimopoulos, E Agapitos and E Patsouris. Minichromosome maintenance
proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with
cell cycle regulators and prognostic implications. Br J Cancer 2007; 98:
1124-1134. (citations: 7)
88.Athanasios
Anagnostopoulos,
Vangelis
Eleftherakis-Papaiakovou,
Konstantinos Zervas, Efstathios Kastritis, Konstantinos Tsionos, Aristotelis
Bamias, John Meletis, Meletios A. Dimopoulos, Evangelos Terpos. Serum
concentrations
of
angiogenic
cytokines
in
Waldenstrom’s
Macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and
angiogenin correlate with disease severity. Br J Haematol 2007; 137: 560568. (citations: 14)
21
89.Bamias A. Editorial Comment on: Impact of Multimodal Treatment on
Survival in Patients with Metastatic Urothelial Cancer. Eur Urol 2007; 52:
1113-1114.
90.Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP,
Skarlos D, Briasoulis E, Konstantara A, Economopoulos T, Dimopoulos
MA. Epithelial ovarian carcinoma in younger vs older women: is age an
independent prognostic factor? The Hellenic Oncology Cooperative Group
experience. Int J Gynecol Cancer. 2007; 17: 1003-1010. (citations: 12)
91.Aristotelis Bamias, Gerassimos Aravantinos, Charalambos Deliveliotis,
Anastasios Thanos, George Klouvas, Nikolaos Antoniou, Iraklis Poulias,
Thomas Makatsoris, Epaminondas Samantas, Meletios A. Dimopoulos.
Two Cycles of Etoposide/Cisplatin Cure All Patients with Stage I Testicular
Seminoma: A Risk Adapted Protocol of the Hellenic Cooperative Oncology
Group. Urology 2007; 70: 1179-1183.
92.Giannis Mountzios, Aristotelis Bamias, Zannis Voulgaris, Alexandros
Rodolakis, Georgios Vlahos, GM Gourgoulis, Evangelos EleftherakisPapaiakovou, A. Giannopoulos. Prognostic factors in patients treated with
Taxane-based chemotherapy for recurrent or metastatic endometrial
cancer: Proposal for a new prognostic model. Gynecol Oncol 2008; 108:
130-135. (citations: 9)
93.Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T,
Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A,
Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA.
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients
with advanced non-small-cell lung cancer. A phase III study of the Hellenic
Cooperative Oncology Group. Ann Oncol 2008; 19: 115-122. (citations:
25)
94.Aristotle Bamias, George Bozas, Nikolaos Antoniou, Iraklis Poulias,
Harilaos Katsifotis, Andreas Skolarikos, Dimitrios Mitropoulos, Christos
Alamanis, Gerassimos Alivizatos, Haralambos Deliveliotis, Meletios A.
Dimopoulos. Prognostic and predictive factors in patients with androgenindependent prostate cancer treated with docetaxel and Estramustine: a
single institution experience. Eur Urol 2008; 53: 323-332. (citations: 13)
95.Aristotle Bamias, Vassiliki Koutsoukou, Evangelos Terpos, Christina
Liakos, Marinos L Tsiatas, Ourania Tsitsilonis, Alexandros Rodolakis,
Zannis Voulgaris, George Vlahos, Theocharis Papageorgiou, George
Papatheodoridis, Athanasios Archimandritis, Aristidis Antsaklis, Meletios A
Dimopoulos. Correlation of NK-T-like CD3+CD56+ cells and
CD4+CD25+(hi) regulatory T cells with VEGF and TNFa in ascites from
advanced ovarian cancer: association with platinum resistance and
prognosis in patients receiving first-line, platinum-based chemotherapy.
Gynecol Oncol 2008; 108:421-427.(citations: 21)
22
96.Bamias A, Dimopoulos MA. Editorial Comment on: New treatment
approaches for prostate cancer based on peptide analogues. Eur Urol.
2008; 899-900.
97.Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z,
Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, Gourgoulis
GM, Efstathiou E, Dimopoulos MA. High-dose melphalan and autologous
stem cell transplantation as consolidation treatment in patients with
chemosensitive ovarian cancer: results of a single-institution randomized
trial. Bone Marrow Transplant 2008; 41: 547-554. (citations: 8)
98.A. Bamias, G. Fountzilas, M. Michael, C. Konstantaras, E. Vrettou, E.
Eleftheriadis, P. Papakostas, K. Papadimitriou, N. Pavlidis, N. Xiros, M.
Bai. DCC and TS protein expression in resected gastric cancer: a Hellenic
Cooperative Oncology Group study. CEJMed 2008; 3: 29-39.
99.Aristotle Bamias, George Lainakis, Efstathios Kastritis, Nikos Antoniou,
Gerassimos Alivizatos, Andreas Koureas, Michael Chrisofos, Andreas
Skolarikos, Evangelos Karayiotis, Meletios A. Dimopoulos. Biweekly
Carboplatin/Gemcitabine in patients with advanced urothelial cancer who
are unfit for cisplatin-based chemotherapy. Report of efficacy, quality of life
and geriatric assessment. Oncology 2007; 73: 290-297. (citations: 9)
100.Papadimitriou, Papakostas, Timotheadou, Aravantinos, Bamias,
Fountzilas. Adjuvant Dose-Dense Sequential Chemotherapy with
Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk
Breast Cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Cancer Invest 2008;26:491-8. (citations: 2)
101.Briasoulis E, Fountzilas G, Bamias A, et al. Multicenter phase II trial of
irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis
cancer of unknown primary. A Hellenic Cooperative Oncology Group study.
Cancer Chemother Pharmacol 2008 ;62(2):277-84. (citations: 5)
102.George Lainakis, Antoniou Nikos, Alivizatos Gerassimos, Chrisofos
Michael, Mitsoyiannis Iraklis, Livadas Konstantinos, Varkarakis Ioannis,
Katsifotis Harilaos, Meletios A. Dimopoulos, Aristotelis Bamias. Biweekly
Doxorubicin/Ketokonazole as second-line treatment in docetaxel-resistant,
hormone-refractory prostate cancer (HRPC). Urology 2008;71(6):1181-5.
(citations: 1)
103.A. Bamias, F. Kyriakou, M. Chorti, et al. Microvessel Density (MVD) and
Cyclooxygenase-2 (COX-2)/ β-catenin Interaction are Associated with
Relapse in Patients with Transitional Carcinoma Receiving Adjuvant
Chemotherapy with Paclitaxel/Carboplatin: a Hellenic Cooperative
Oncology Group (HECOG) Study. Anticancer Res 2008; 28:2479-86.
(citations: 2)
104.Papadimitriou CA, Fountzilas G, Bafaloukos D, Bozas G, Kalofonos H,
Pectasides D, Aravantinos G, Bamias A, Dimopoulos MA. Paclitaxel,
23
topotecan, and carboplatin in metastatic endometrial cancinoma: A Hellenic
Co-operative Oncology Group (HeCOG) study. Gynecol Oncol
2008;111:27-34. (citations: 3)
105.Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G,
Samantas E, Karina M, Misailidou D, Pisanidis N, Pentheroudakis G,
Economopoulos T, Papadimitriou C, Skarlos DV, Pectasides D,
Stavropoulos M, Bafaloukos D, Kardamakis D, Karanikiotis C, Vourli G,
Fountzilas G. A randomised phase III trial of adjuvant radio-chemotherapy
comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in
patients with rectal cancer: A Hellenic Cooperative Oncology Group Study.
Eur J Cancer 2008;44:1693-700. (citations: 6)
106.Gerasimos Aravantinos; George Fountzilas; Aristotelis Bamias; Irene
Grimani; Spyridon Rizos; Haralabos P Kalofonos; Dimosthenis V Skarlos;
Theofanis Economopoulos; Paris A Kosmidis; George P Stathopoulos;
Evangelos Briasoulis; Dimitrios Pectasides; Epaminondas Samantas; Eleni
Timotheadou; Christos Papadimitriou; Alexandros Papanikolaou; Adimchi
Onyenadum; Pavlos Papakostas; Dimitrios Bafaloukos; Meletios A
Dimopoulos. Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and
Doxorubicin for first line Chemotherapy of Advanced Ovarian Cancer. Eur
J Cancer 2008; 44:2169-2177. (citations: 5)
107.Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G,
Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E,
Bamias A, Pavlidis N. Docetaxel and carboplatin combination
chemotherapy as outpatient palliative therapy in carcinoma of unknown
primary: A multicentre Hellenic Cooperative Oncology Group phase II
study. Acta Oncol 2008; 3:1-8. (citations: 12)
108.Lainakis G, Bamias A.Targeting angiogenesis in renal cell carcinoma.
Curr Cancer Drug Targets. 2008;8(5):349-58. (citations: 12)
109.Papadimitriou CA, Peitsidis P, Bozas G, Grimani I, Vlahos G, Rodolakis
A, Lianos E, Bamias A, Lainakis G, Dimopoulos MA. Paclitaxel- and
Platinum-Based Postoperative Chemotherapy for Primary Fallopian Tube
Carcinoma: A Single Institution Experience. Oncology. 2008; 75(1-2):4248. (citations: 2)
110.Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard
X, Dogliotti L, Conti G, Turesson I, James N, Heidenreich A, Solsona E,
Guillem V, Herchenhorn D, Moul J, van Moorselaar J, Coetzee LJ, Wilson
A, Bamias A, De Wit R, Chrisofos M. Optimizing treatment for men with
advanced prostate cancer: Expert recommendations and the
multidisciplinary approach. Crit Rev Oncol Hematol. 2008; 68S: 9-22.
(citations: 13)
111.Dellis AE, Demonakou M, Papatsoris AG, Chrisofos M, Bamias A,
Deliveliotis C. Insight into long-term histological, proliferative and apoptotic
24
modifications in ileal orthotopic neobladder and conduit mucosa. Tumori.
2008 Sep-Oct;94(5):701-5. (citations: 2)
112.Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou
M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E,
Bamias A. Reduction of osteonecrosis of the jaw (ONJ) after
implementation of preventive measures in patients with multiple myeloma
treated with zoledronic acid. Ann Oncol. 2009; 20(1):117-20. (citations: 84)
113.Efstathios Kastritis, Samuel Murray, Fani Kyriakou, Maria Horti, Nicolaos
Tamvakis, Nicolaos Kavantzas, Efstratios S. Patsouris, Aphrodite Noni,
Sofia Legaki, Meletios A. Dimopoulos, Aristotle Bamias. Somatic APC
mutations and nuclear b-catenin accumulation have prognostic significance
in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int
J Cancer 2009; 124(1):103-8. (citations: 13)
114.Aristotle Bamias. Editorial Comment on: Can Tyrosine Kinase Inhibitors
be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a
Complete Response to Treatment? A Multicentre, Retrospective Analysis.
Eur Urol 2009; 55: 1439.
115.G. Fountzilas, A. Bamias, A. Kalogera-Fountzila, G. Karayiannopoulou, et
al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by
Concomitant Chemoradiotherapy in Patients with Inoperable Nonnasopharyngeal Carcinoma of the Head and Neck . Anticaner Res 2009;
29: 529-538. (citations: 7)
116. Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A,
Bamias A, Dimopoulos MA, Constantinou AI, Tsitsilonis OE. Phenoxodiol,
an anticancer isoflavene, induces immunomodulatory effects in vitro and in
vivo. J Cell Mol Med 2009; 13: 3929-3938. (citations: 4)
117.Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Bamias A et
al. Epithelial ovarian cancer in Greece: a retrospective study of 1,791
patients by the Hellenic Cooperative Oncology Group (HeCOG).
Anticancer Res. 2009 Feb;29(2):745-51. (citations: 4)
118.Aristotle Bamias, George Lainakis, Efstathios Manios, Eleni Koroboki,
Alexandra Karadimou, Nikos Zakopoulos and Meletios A. Dimopoulos.
Could Rigorous Diagnosis and Management of Hypertension Reduce
Cardiac Events in Patients With Renal Cell Carcinoma Treated With
Tyrosine Kinase Inhibitors? J Clin Oncol 2009; 27(15):2567-9. (citations:
6)
119.Bamias A, Aravantinos G, Kastriotis I, Alivizatos G, Anastasiou I,
Christodoulou C, Gyftaki R, Kalofonos HP, Dimopoulos MA. Report of the
long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in
patients with stage I testicular nonseminomatous germ-cell tumors
(NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology
Group. Urol Oncol. 2011; 29: 189-193.
25
120.Mountzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H,
Aravantinos G, Fountzilas G, Papadimitriou CA. Randomized multicenter
phase II trial of cisplatin and ifosfamide with or without paclitaxel in
recurrent or metastatic carcinoma of the uterine cervix: a Hellenic
Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2009; 20: 13621368. (citations: 3)
121. Mountzios J, Bamias A. Cisplatin-based chemotherapy for advanced
seminoma: report of 52 cases treated in two institutions. J Cancer Res
Clin Oncol 2009 (in press).
122.A. Bamias, G. Lainakis, E. Manios, E. Koroboki, R. Gyftaki, N.
Zakopoulos, M.A. Dimopoulos. Diagnosis and management of
hypertension in advanced renal cell carcinoma: prospective evaluation of
an algorithm in patients treated with Sunitinib. J Chemother 2009; 3: 347350. (citations: 5)
123.Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA.
Sunitinib treatment in patients with severe renal function impairment: a
report of four cases by the Hellenic Cooperative Oncology Group. Clin
Nephrol. 2009;72(1):73-8. (citations: 5)
124.Marinos Tsiatas, Reveka Gyftaki, Cristine Liacos, Ekaterini Politi,
Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Aristotelis
Bamias. Study of T lymphocytes infiltrating peritoneal metastases in
advanced ovarian cancer. Associations with VEGF levels and prognosis in
patients receiving platinum-based chemotherapy. Int J Gynecol Cancer
2009; 1329-1334. (citations: 4)
125.Zagouri F, Papaefthimiou M, Chalazonitis AN, Antoniou N, Dimopoulos
MA, Bamias A. Prostate Cancer with Metastasis to the Omentum and
Massive Ascites: A Rare Manifestation of a Common Disease. Onkologie
2009;32(12):758-761. (citations: 1)
126.G. Mountzios, A. Bamias, A. Dalianis, P. Danias, E. Pantelidaki, J.
Nanas, M.A. Dimopoulos. Endocardial metastases as the only site of
relapse in a patient with bladder carcinoma: A case report and review of the
literature. Int J Cardiol 2010; 140: E4-E7. (citations: 2)
127.Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A,
Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T,
Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D,
Dimopoulos AM. A randomized phase II study of carboplatin plus pegylated
liposomal doxorubicin versus carboplatin plus paclitaxel in platinum
sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group
study. BMC Med. 2010;8(1):3. (citations: 6)
128.N. Gavalas, MA Dimopoulos, A. Bamias. Anti-tumor immune response in
ovarian cancer: clinical implications, prognostic significance and potential
26
for novel treatment strategies. Oncol Rev DOI: 10.1007/s12156-009-00165.
129.Boskos CS, Liacos C, Korkolis D, Aygerinos K, Lamproglou I, Terpos E,
Stoupa E, Baltatzis G, Beroukas K, Papasavvas P, Dimopoulos MA, Bamias
A. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a
predictive factor of response to preoperative chemoradiation with
capecitabine in patients with advanced rectal cancer. J Surg Oncol. 2010;
102: 408-412. (citations: 1)
130.Aristotle Bamias, Theodora Psaltopoulou, M. Sotiropoulou, Dimitrios
Haidopoulos, Evangelos Lianos, Evangelos Bournakis, Christos
Papadimitriou, A. Rodolakis, G. Vlahos, M. A. Dimopoulos. Mucinous But
Not Clear Cell Histology Is Associated With Inferior Survival in Patients
With Advanced Stage Ovarian Carcinoma Treated With Platinum-paclitaxel
Chemotherapy. Cancer 2010; 116: 1462-8. (citations: 11)
131.A. Karadimou, MA Dimopoulos, A. Bamias. The role of high-dose
chemotherapy in the treatment of testicular cancer. Open Access Journal
of Urology 2010; 2: 25-30. (citations: 1)
132.Bozas G, Terpos E, Gika D, Karadimou A, Dimopoulos MA, Bamias A.
Prechemotherapy Serum Levels of CD105, Transforming Growth Factor
beta2, and Vascular Endothelial Growth Factor Are Associated With
Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated
With Cytoreductive Surgery and Platinum-Based Chemotherapy. Int J
Gynecol Cancer 2010 20(2):248-54.
133.Ignace Vergote, Eric Pujade-Lauraine, Sandro Pignata, Gunnar B.
Kristensen, Jonathan Ledermann, Antonio Casado, Jalid Sehouli, Mansoor
Mirza, Roldano Fossati, Christian Marth, Carine Creutzberg, Jose Del
Campo, Nadeem Siddiqui, Paula Calvert, Aris Bamias, Gokhan Tulunay,
Ate G.J. van der Zee, and Andreas du Bois, MD,* on behalf of the member
trial groups of the European Network of Gynaecological Oncological Trial
Groups (ENGOT). European Network of Gynaecological Oncological Trial
Groups’ Requirements for Trials Between Academic Groups and
Pharmaceutical Companies. Int J Gynecol Cancer 2010;20: 476-478.
134.Aristotelis Bamias, Alexandra Karadimou, Sofia Lampaki, George
Lainakis, Lia Malettou, Eleni Timotheadou, Kostas Papazisis, Charalambos
Andreadis, Loukas Kontovinis, Ioannis Anastasiou, Kostas Stravodimos,
Ioannis Xanthakis, Andreas Skolarikos, Christos Christodoulou, Kostas
Syrigos, Christos Papandreou, Evangelia Razi, Urania Dafni, George
Fountzilas, Meletios A Dimopoulos. Prognostic stratification of patients with
advanced renal cell carcinoma treated with sunitinib: comparison with the
Memorial Sloan-Kettering prognostic factors model. BMC Cancer 2010; 10:
45. (citations: 3)
135.Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G,
Bamias A, Mavrikakis M, Dimopoulos MA. Markers of bone remodeling and
27
skeletal morbidity in patients with solid tumors metastatic to the skeleton
receiving the biphosphonate zoledronic acid. Transl Res. 2010;155(5):24755. (citations: 4)
136.Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G,
Samantas E, Christodoulou C, Pentheroudakis G, Pectasides D,
Dimopoulos MA, Fountzilas G. A randomized phase III study of adjuvant
platinum/docetaxel chemotherapy with or without radiation therapy in
patients with gastric cancer. Cancer Chemother Pharmacol 2010; 65:
1009-1021. (citations: 8)
137.Aristotle Bamias, Evangelos Terpos Meletios A. Dimopoulos. Avascular
Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment.
Onkologie 2010; 33: 288-289 (Editorial).
138.Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V;
ESMO Guidelines Working Group. Collaborators (63): Schmoll HJ, Laguna
MP, Fizazi K, Horwich A, Albers P, Albrecht W, Algaba F, Bamias A,
Bodrogi I, Cohn-Cedermark G, Culine S, Cullen M, Daugaard G, De Santis
M, De Wit R, Derigs G, Dieckmann K, Droz JP, Einhorn L, Fléchon A,
Fossa S, Foster RS, Solans JG, Gauler T, Géczi L, Lluch JR, Gillessen S,
Gosporadowicz M, Hartmann M, Huddart R, Jewett M, Joffe J, Jordan K,
Kataja V, Klepp O, Kollmannsberger C, Krege S, Looijenga L, Mead GM,
Necchi A, Nichols C, Nicolai N, Oliver T, Ondrus D, Osterhuis W, Paz-Ares
L, Powles T, Pottek T, Rajpert-De Meyts E, Rosti G, Rustin G, Salvioni R,
Schmidberger H, Sedlmayer F, Sella A, Sippel C, Skakkebaek NE, Sohaib
A, Tjulandin S, van den Belt-Dusebout AW, von der Maase H, Warde P,
Wood L. Testicular non-seminoma: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl
5:v147-54. (citations: 11)
139.Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V;
ESMO Guidelines Working Group. Collaborators (63): Schmoll HJ, Laguna
MP, Fizazi K, Horwich A, Albers P, Albrecht W, Algaba F, Bamias A,
Bodrogi I, Cohn-Cedermark G, Culine S, Cullen M, Daugaard G, De Santis
M, De Wit R, Derigs G, Dieckmann K, Droz JP, Einhorn L, Fléchon A,
Fossa S, Foster RS, Solans JG, Gauler T, Géczi L, Lluch JR, Gillessen S,
Gosporadowicz M, Hartmann M, Huddart R, Jewett M, Joffe J, Jordan K,
Kataja V, Klepp O, Kollmannsberger C, Krege S, Looijenga L, Mead GM,
Necchi A, Nichols C, Nicolai N, Oliver T, Ondrus D, Osterhuis W, Paz-Ares
L, Powles T, Pottek T, Rajpert-De Meyts E, Rosti G, Rustin G, Salvioni R,
Schmidberger H, Sedlmayer F, Sella A, Sippel C, Skakkebaek NE, Sohaib
A, Tjulandin S, van den Belt-Dusebout AW, von der Maase H, Warde P,
Wood L. Testicular seminoma: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl
5:v140-6. (citations: 5)
140.Karadimou A, Lianos E, Pectasides D, Dimopoulos MA, Bamias A.
Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in
28
gemcitabine-pretreated patients with advanced urothelial cancer: a
retrospective analysis. Open Access Urology 2010; 2: 1-7.
141.Mattheos Bobos • Aristotelis Bamias. In response to Dr. Han’s comments.
Cancer Chemother Pharmacol. 2010; DOI 10.1007/s00280-010-1491-x.
142.Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA,
Pentheroudakis G, Samantas E, Bamias A, et al. A randomised phase III
trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil
versus leucovorin and fluorouracil for stage II and III colon cancer : A
Hellenic Cooperative Oncology Group study. BMC Med 2011; 9: 10.
(citations: 3)
143.Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A,
Paraskevopoulos P, Dimopoulos M, Papazisis K. Sequential treatment with
sorafenib and sunitinib in metastatic renal cell carcinoma : clnical outcomes
from a retrospective clinical study. Med Oncol 2011. (citations: 1)
144.Bamias A, Gavalas NG, Karadimou A, Dimopoulos MA. Immune
response in ovarian cancer: how is the immune system involved in
prognosis and therapy: potential for treatment utilization. Clin Dev
Immunol 2010; 2010: 791603 (Epub). (citations: 1)
145.George Lainakis, Alexandra Karadimou, Athanasios Meletios
Dimopoulos, Aristotelis Bamias. Bevacizumab in the treatment Of
metastatic renal cell carcinoma (mRCC). FCO 2010; Special Issue 1: 5057.
146.Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M,
Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A,
Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent
docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Urology 2011; 77: 682-687. (citations: 3)
147.Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C,
Alamanis C, anastassiou I, Constantinides C, Bamias A, Dimopoulos MA.
Time to castration resistance is an independent predictor of castrationresistant prostate cancer survival. Anticancer Res 2011; 31: 1475-1482.
148.Ziogas AC, Gavalas N, Tsiatas M, Tsitsilonis O, Politi E, Terpos E,
Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A,
Dimopoulos MA, Bamias A. VEGF directly suppresses activation of T cells
from ovarian cancer patients and healthy individuals via VEGF receptor
type 2. Int J Cancer 2012, 130: 857-864.
149.A. Bamias, E. Manios, A. Karadimou, F. Michas, G. Lainakis, C.
Constantinidis, C. Deliveliotis, N. Zakopoulos, M.A. Dimopoulos. The use of
24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of
sunitinib improves the diagnostic accuracy and management of
29
hypertension in patients with advanced renal cancer. Eur J Cancer 2011,
47: 1660-1668, doi:10.1016/j.ejca.2011.03.03 (citations: 1)
150.Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D,
Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX,
Hurel S, Guy L, Bigot P, Roumiguié M, Rouprêt M; for the French
collaborative national database on UUT-UCC. Outcomes after adjuvant
chemotherapy in the treatment of high-risk urothelial carcinoma of the
upper urinary tract (UUT-UC): Results From a Large Multicenter
Collaborative Study. Cancer 2011; 117: 5500-5508. (citations: 1)
151.Bournakis E, Dimopoulos MA, Bamias A. Management of advanced
bladder cancer in patients with impaired renal function. Expert Review of
Anticancer Therapy 2011; 11: 931-939, doi 10.1586/era.10.197.
152.A. Bamias, A. Karadimou, N. Soupos, M. Sotiropoulou, F. Zagouri, D.
Haidopoulos, N. Thomakos, A. Rodolakis, A. Antsaklis and M.A.
Dimopoulos. Prognostic factors for early-stage epithelial ovarian cancer,
treated with adjuvant carboplatin/paclitaxel chemotherapy: A single
institution
experience.
Gynecol
Oncol
2011;
doi:10.1016/j.ygyno.2011.06.033.
153.Karadimou A, Migou M, Economidi A, Stratigos A, Kittas C, Dimopoulos
MA, Bamias A. Leukocytoclastic vasculitis after long-term treatment with
sunitinib: a case report. Case Rep Oncol 2011;4:385-391 (DOI:
10.1159/000331419).
154.A. Bamias, M. Sotiropoulou, F. Zagouri, P. Trachana, K. Sakellariou, E.
Kostouros, K. Kakoyianni, A. Rodolakis, G. Vlahos, D. Haidopoulos, N.
Thomakos, A. Antsaklis, M.A. Dimopoulos. Prognostic evaluation of tumour
type and other histopathological characteristics in advanced epithelial
ovarian cancer, treated with surgery and paclitaxel/carboplatin
chemotherapy: Cell type is the most useful prognostic factor. Eur J Cancer
2011, doi:10.1016/j.ejca.2011.09.023.
155.Christodoulos Stefanadis, Andreas Synetos, Dimitris Tousoulis,
Eleftherios Tsiamis, Archontoula Michelongona, Flora Zagouri, Aristotle
Bamias, Meletios Athanasios Dimopoulos, Stella Kyvelou, Ioannis
Kapelakis, Konstantinos Toutouzas. Systemic administration of
bevacizumab increases the risk of cardiovascular events in patients with
metastatic cancer. Int J Cardiol 2011, doi:10.1016/j.ijcard.2011.10.115.
156.Elias Athanassiadis, Vassilis Georgoulias, Charalampos Kalophonos,
Paris Kosmidis, Aristotelis Bamias, Vassilios Barbounis, Ioannis
Boukovinas, Dimitrios Pectasides, Epameinondas Samantas, Dimosthenis
Skarlos; On behalf of non-infectious pneumonitis study group. Consensus
on the better diagnosis, treatment and management of non-infectious
pneumonitis. FCO 2011; 2: 37-39.
30
157.Morris DN, Bamias AT. Drugs for the treatment of advanced/metastatic
renal cancer: Current perspectives Archives of Hellenic Medicine 2011;
28: 450-459.
158.Aristotle Bamias, Christina Bamia, Alexandra Karadimou, Nikolaos
Soupos, Flora Zagouri, Alexandros Rodolakis, Dimitrios Haidopoulos,
George Vlahos, Nikos Thomakos, Aristidis Antsaklis, Meletios A.
Dimopoulos. A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in
Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles
on Outcome. Oncology 2012;81:365-371 (DOI: 10.1159/000334230).
159.I. Vergote, E. Pujade-Lauraine, S. Pignata, GB Kristensen. J Ledermann,
A. Casado, J Sehouli, M. Mirza, R. Fossati, C. Marth, N ottevanger, J. Del
campo, N. Siddiqui, P. Calvert, A. Bamias, G. Tulunay, AGJ Van der Zee,
A. du Bois. The European Network of Gynaecological Oncological Trial
Groups. Clin Invest 2012; 2: 35-37.
160.Emmanouil Panagiotidis, Ioannis Emmanouil Datseris, Demetrios
Exarhos, Maria Skilakaki, Evangelia Skoura and Aristotelis Bamias. High
incidence of peritoneal implants in recurrence of intra-abdominal cancer
revealed by 18F-FDG PET/CT in patients with increased tumor markers
and negative findings on conventional imaging. Nuclear Medicine
Communications 2012 DOI: 10.1097/MNM.0b013e3283506ae1.
161.Nicolaou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D,
Economopoulos T, Raber-Durlacher JE, Dimitriades G, Dimopoulos MA.
Gingival bleeding and jaw bone necorosis in aptients with metastatic renal
cell carcinoma receiving sunitinib: Report of 2 cases with clinical
implications. Oral Surgery, Oral Medicine, Oral Pathology, Oral
Radiology 2012; 113: 234-238.
162.Flora Zagouri, Nikolaos Thomakos, Alexandros Rodolakis, Aristotle
Bamias, Athanassios Chalazonitis, Maria Sotiropoulou, Aris Antsaklis,
Meletios-Athanassios Dimopoulos, Christos A. Papadimitriou. Quiz Case: A
19-Year-Old Woman with Hypercalcemia and Abdominal Pain. Onkologie
2012; 35: 126–127 (letter).
163.Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkotzamanidou
M, Bamia C, Liakou C, Bekyrou M, Sfikakis PP, Dimopoulos MA, Souliotis
VL. Development and validation of a PCR-based assay for the selection of
patients more likely to benefit from therapeutic treatment with alkylating
drugs. Br J Clin Pharmacol 2012. doi: 10.1111/j.1365-2125.2012.04274.x.
164.Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH,
Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R,
Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.
Collaborators (253) : ….Bamias A…... An international expanded-access
programme of everolimus: addressing safety and efficacy in patients with
metastatic renal cell carcinoma who progress after initial vascular
31
endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J
Cancer. 2012;48:324-32.
165. Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: A promising
therapeutic target for ovarian cancer. Crit Rev Oncol/Hematol 2012,
http://dx.doi.org/10.1016/j.critrevonc.2012.04.002
166. Thomakos N, Zacharakis D, Akrivos N, Zagouri F, Simou M, Bamias A,
Dimopoulos MA, Rodolakis A, Antsaklis A. Merkel cell carcinoma in pelvic
lymph nodes after surgical staging for endometrial cancer: A case report and
review of the literature. Int J Surg Case Rep. 2012; 3: 340-342.
167. Levidou G, Ventouri K, Nonni A, Gakiopoulou H, Bamias A,
Sotiropoulou M, Papaspirou I, Dimopoulos MA, Patsouris E, Korkolopoulou P.
Replication Protein A in Nonearly Ovarian Adenocarcinomas: Correlation With
MCM-2, MCM-5, Ki-67 Index and Prognostic Significance. Int J Gynecol
Pathol. 2012;31:319-27.
168. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I,
Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J,
Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Randomized, OpenLabel, Phase III Study Comparing Patupilone (EPO906) With Pegylated
Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With
Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal
Cancer. J Clin Oncol. 2012. [Epub ahead of print].
169. A. Bamias, U. Dafni, A. Karadimou, E. Timotheadou, G. Aravantinos,
A. Psyrri, I. Xanthakis, M. Tsiatas, V. Koutoulidis, C. Constantinidis, C.
Hatzimouratidis, E. Samantas, A. Visvikis, M. Chrisophos, K. Stravodimos, C.
Deliveliotis, A. Eleftheraki, D. Pectasides, G. Fountzilas, M. A. Dimopoulos.
Prospective, open-label, randomized, phase III study of two dose-dense
regimens MVAC versus gemcitabine/ cisplatin in patients with inoperable,
metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology
Group study (HE 16/03). Ann Oncol 2012 doi:10.1093/annonc/mds583.
170. Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis
V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G,
Dimopoulos MA, Bamias A. Association of ERCC1 SNPs with outcome in
platinum-treated patients with advanced urothelial cancer: a Hellenic
Cooperative Oncology Group study. Pharmacogenomics. 2012;13:1595607.
171. Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC,
Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A,
Dimopoulos MA, Bamias A. VEGF directly suppresses activation of T cells
from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J
Cancer 2012;107:1869-75.
32
172. Cecere SC, Pisano C, Bamias A, Di Napoli M, Rossetti S, Facchini G,
Tambaro R, Pignata S. Multidisciplinary Treatment of Early Stage Endometrial
Cancer. Anticancer Agents Med Chem. 2012.
173. Zacharakis D, Thomakos N, Biliatis I, Rodolakis A, Simou M,
Daskalakis G, Bamias A, Antsaklis A. Ultrasonographic markers and
preoperative CA-125 to distinguish between borderline ovarian tumors and
stage I ovarian cancer. Acta Obstet Gynecol Scand. 2012. doi:
10.1111/aogs.12046.
174. Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis
A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
Improved Survival Trends in Platinum-Resistant Patients with Advanced
Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line
Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents. Oncology.
2012;84(3):158-165.
175. Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T,
Mavrothalassiti I, Spyrou S, Dimopoulos MA, Tsitsilonis OE, Bamias A.
Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α
or its immunoactive decapeptide lyse autologous tumour cells in vitro and
retard tumour growth in SCID mice. Eur J Cancer. 2012 doi:pii: S09598049(12)00956-2. 10.1016/j.ejca.2012.11.037.
176. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde
G, Godbold J, Oh WK, Bamias A. Cisplatin-based combination chemotherapy
in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2013.
doi:pii: S1078-1439(12)00394-8. 10.1016/j.urolonc.2012.11.001.
177. Alexandra V. Stavropoulou, Florentia Fostira, Maroulio Pertesi, Marianthi
Tsitlaidou, Gerassimos E. Voutsinas, Olga Triantafyllidou, Aristotelis Bamias,
Meletios A. Dimopoulos, Eleni Timotheadou, Dimitrios Pectasides, Christos
Christodoulou, George Klouvas, Christos Papadimitriou, Thomas Makatsoris,
George Pentheroudakis, Gerasimos Aravantinos, Vassilis Karydakis,
Drakoulis Yannoukakos, George Fountzilas, Irene Konstantopoulou.
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian
Cancer Cases. PloS ONE 2013; 8(3): e58182.
doi:10.1371/journal.pone.0058182.
178. Maria Alevizaki, Elena Kyratzoglou, Aristoteles Bamias, Marinella
Tzanela, Meletios A. Dimopoulos, Katerina Saltiki. Metachronous appearance
of second malignancies in medullary thyroid carcinoma (MTC) patients: a
diagnostic challenge and brief review of the literature. Endocrine 2013.
179. Lindsay Haines, Aristotle Bamias, Susan Krege, Chia-Chi Lin, Noah
Hahn,Thorsten H. Ecke, Erin Moshier, Guru Sonpavde, James Godbold,
William K. Oh, Matthew D. Galsky. The Impact of Gender on Outcomes in
Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary
Cancer 2013.
33
180. Matthew D. Galsky; Erin Moshier; Susan Krege; Chia-Chi Lin; Noah
Hahn; Thorsten Ecke; Guru Sonpavde; James Godbold; William K. Oh;
Aristotle Bamias. Nomogram for Predicting Survival in Patients With
Unresectable and/or Metastatic Urothelial Cancer Who Are Treated With
Cisplatin-Based Chemotherapy. Cancer 2013, doi: 10.1002/cncr.28146.
181. Matthew D. Galsky; Susan Krege; Chia-Chi Lin; Noah Hahn; Thorsten
Ecke; Erin Moshier; Guru Sonpavde; James Godbold; William K. Oh; Aristotle
Bamias. Relationship Between 6- and 9-Month Progression-Free Survival and
Overall Survival in Patients With Metastatic Urothelial Cancer Treated With
First-Line Cisplatin-Based Chemotherapy. Cancer 2013; doi:
10.1002/cncr.28145.
182. Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B,
Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E,
Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia
C. Development and validation of a prognostic model in patients with
metastatic renal cell carcinoma treated with sunitinib: a European
collaboration. Br J Cancer. 2013; 109(2):332-41. doi: 10.1038/bjc.2013.341.
183. Nikos G. Gavalas, Michalis Liontos, Sofia-Paraskevi Trachana, Tina
Bagratuni, Calliope Arapinis, Christine Liacos, Meletios A. Dimopoulos and
Aristotle Bamias. Angiogenesis-Related Pathways in the Pathogenesis of
Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 15885-15909;
doi:10.3390/ijms140815885.
184. Nils Kroeger, Toni K. Choueiri, Jae-Lyn Lee, Georg A. Bjarnason,
Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N.
Vaishamayan, Sun-Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede
Donskov, Neeraj Agarwal, Min-Han Tan, Aristotelis Bamis, Christian K.
Kollmannsberger, Scott A. North, Brian I. Rini, Daniel Y.C. Heng. Survival
Outcome and Treatment Response of Patients with Late Relapse from
RenalCell Carcinoma in the Era of Targeted Therapy. Eur Urol 2013.
http://dx.doi.org/10.1016/j.eururo.2013.07.031
34